Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of the open offer

4 Apr 2016 10:17

RNS Number : 0454U
Scancell Holdings Plc
04 April 2016
 

04 April 2016

 

Scancell Holdings Plc

("Scancell" or the "Company")

 

Result of the open offer

 

On 1 April 2016 the Board of Scancell announced that it had received subscriptions in respect of 16,048,593 new Ordinary Shares of the 22,495,068 new Ordinary Shares available under the Open Offer.

 

The Company has now received applications for an additional 558,823 new Ordinary Shares, available but not subscribed for by Qualifying Shareholders in the Open Offer, therefore the revised total subscription under the Open Offer is 16,607,416 new Ordinary Shares, representing 73.8 per cent. the new Ordinary Shares available under the Open Offer. The Company has therefore raised gross proceeds of approximately £2.8 million through the Open Offer and £3.4 million through the Placing being approximately £6.2 million in total.

 

Application will be made to the London Stock Exchange for the admission to trading on AIM of the 36,607,416 new Ordinary Shares to be issued under the Placing and Open Offer. It is expected that Admission will occur and that dealings will commence at 08:00 a.m. on 5 April 2016. The total number of Ordinary Shares following Admission will be 261,558,099 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in Scancell under the FCA's Disclosure and Transparency Rules.

 

This announcement should be read in conjunction with the full text of the Circular posted to Shareholders on 11 March 2016, copies of which are available on the Company's website at www.scancell.co.uk. Capitalised terms not otherwise defined in this announcement have the meanings given in the Circular. 

 

 

For further information please contact:

 

Scancell Holdings Plc

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

+44 (0) 20 3727 1000

Panmure Gordon (Nominated Adviser and placing agent)

Robert Naylor/Paul Fincham, Corporate Finance

Maisie Atkinson, Sales

+44 (0) 20 7886 2500

Lesmoir-Gordon, Boyle & Co. Limited (Sub placing agent)

Angus Grierson

+44 (0) 20 7518 9892

FTI Consulting

Mo Noonan

Simon Conway

+44 (0) 20 3727 1000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEMMGGDLDFGVZG
Date   Source Headline
5th Oct 20214:22 pmRNSFirst subject dosed in COVIDITY clinical trial
9th Sep 20214:31 pmRNSPDMR dealing
26th Aug 20217:00 amRNSModi-1 Phase I/II CTA approved by MHRA
17th Aug 20217:00 amRNSScancell selects PharmaJet’s Needle-free Systems
30th Jul 20219:52 amRNSDirector Dealing
29th Jul 20217:00 amRNSCOVIDITY Phase 1 trial application in SA approved
28th Jul 20215:00 pmRNSLindy Durrant appointed CEO of Scancell
22nd Jun 20217:00 amRNSCOVIDITY trial planned in South Africa and UK
15th Jun 20217:00 amRNSAppointment of Joint Broker
8th Jun 20214:41 pmRNSSecond Price Monitoring Extn
8th Jun 20214:35 pmRNSPrice Monitoring Extension
7th Jun 20218:49 amRNSDirector Dealing
30th Apr 202110:48 amRNSDirector Dealing
10th Mar 20219:58 amRNSHolding(s) in Company
2nd Mar 20214:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20213:00 pmRNSDirector Dealing
19th Feb 20217:00 amRNSDirector Dealing
17th Feb 20212:04 pmRNSDirector Dealing
16th Feb 20213:00 pmRNSBLOCK LISTING SIX MONTHLY RETURN
15th Feb 20213:36 pmRNSStatement regarding share price movement
15th Feb 202111:05 amRNSSecond Price Monitoring Extn
15th Feb 202111:00 amRNSPrice Monitoring Extension
15th Feb 20219:05 amRNSSecond Price Monitoring Extn
15th Feb 20219:00 amRNSPrice Monitoring Extension
3rd Feb 20217:00 amRNSUpdate on SCIB2 clinical development partnership
29th Jan 20217:00 amRNSInterim Results for the 6 months ended 31 Oct 2020
30th Dec 20202:00 pmRNSPrice Monitoring Extension
30th Dec 202011:05 amRNSSecond Price Monitoring Extn
30th Dec 202011:00 amRNSPrice Monitoring Extension
18th Dec 20204:41 pmRNSSecond Price Monitoring Extn
18th Dec 20204:35 pmRNSPrice Monitoring Extension
18th Dec 20202:05 pmRNSSecond Price Monitoring Extn
18th Dec 20202:00 pmRNSPrice Monitoring Extension
18th Dec 20207:00 amRNSCOVID-19 vaccine candidate selected
15th Dec 20203:45 pmRNSDirector Dealing
14th Dec 20201:03 pmRNSDirector Dealing
25th Nov 202011:26 amRNSDirector Dealing
17th Nov 20202:34 pmRNSResults of Annual General Meeting
17th Nov 202012:00 pmRNSAppointment of CMO and Medical Director
13th Nov 202012:36 pmRNSDirector Dealing
10th Nov 20202:44 pmRNSDirector Dealing
9th Nov 20202:06 pmRNSSecond Price Monitoring Extn
9th Nov 20202:01 pmRNSPrice Monitoring Extension
6th Nov 202011:49 amRNSHolding(s) in Company
5th Nov 202010:51 amRNSResult of Adjourned General Meeting
3rd Nov 20208:33 amRNSHolding(s) in Company
2nd Nov 20205:00 pmRNSConvertible Loan Notes & Total Voting Rights
29th Oct 202010:15 amRNSResult of Open Offer and Adjournment of GM
27th Oct 20204:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.